Lipocine Inc. (LPCN)
NASDAQ: LPCN · Real-Time Price · USD
2.200
+0.100 (4.76%)
At close: Oct 7, 2026, 4:00 PM EDT
2.020
-0.180 (-8.18%)
After-hours: Oct 7, 2026, 7:59 PM EDT
Lipocine Revenue
Lipocine had revenue of $190.10K in the quarter ending June 30, 2026, a decrease of -69.48%. This brings the company's revenue in the last twelve months to $1.57M, down -62.70% year-over-year. In the year 2025, Lipocine had annual revenue of $1.98M, down -82.35%. That makes Lipocine the world's 42,821st largest company by revenue and 5,891st in the United States.
Revenue (ttm)
$1.57M
Revenue Growth
-62.70%
P/S Ratio
11.56
Revenue / Employee
$112,104
Employees
14
Market Cap
18.14M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.98M | -9.22M | -82.35% |
| Dec 31, 2024 | 11.20M | 8.13M | 264.67% |
| Dec 31, 2023 | 3.07M | 2.57M | 514.16% |
| Dec 31, 2022 | 500.00K | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | 164.99K | -263.04K | -61.45% |
| Dec 31, 2018 | 428.03K | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | 7.71M | - | - |
| Dec 31, 2011 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Palatin Technologies | 13.19M |
| TScan Therapeutics | 7.11M |
| Dyadic International | 3.80M |
| Marker Therapeutics | 3.55M |
| Neuphoria Therapeutics | 1.17M |
| Allarity Therapeutics | 345.00K |
| Kiora Pharmaceuticals | 20.00K |
| BioCardia | 3.00K |
LPCN News
- 17 hours ago - Lipocine announces Health Canada approved TLANDO capsules - TheFly
- 18 hours ago - Lipocine Announces Health Canada Approval of TLANDO® for Testosterone Replacement Therapy - PRNewsWire
- 16 days ago - H.C. Wainwright sets $4 price target on Lipocine - TheFly
- 21 days ago - Lipocine Slides: Conference Presentation - Filings
- 23 days ago - Lipocine initiates Phase 3 study of LPCN 1154 for postpartum depression - TheFly
- 23 days ago - Lipocine Announces Initiation of BLOOM Phase 3 Study of LPCN 1154 for Postpartum Depression - PRNewsWire
- 27 days ago - Lipocine to Present at the H.C. Wainwright 28th Annual Global Investment Conference - PRNewsWire
- 2 months ago - Lipocine reports Q2 EPS (32c) vs. (41c) last year - TheFly